Wuxi Biologics Stock Fundamentals
| WXIBF Stock | USD 1.86 0.00 0.00% |
WuXi Biologics fundamentals help investors to digest information that contributes to WuXi Biologics' financial success or failures. It also enables traders to predict the movement of WuXi Pink Sheet. The fundamental analysis module provides a way to measure WuXi Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to WuXi Biologics pink sheet.
WuXi |
WuXi Biologics Company Shares Outstanding Analysis
WuXi Biologics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current WuXi Biologics Shares Outstanding | 4.22 B |
Most of WuXi Biologics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, WuXi Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, WuXi Biologics has 4.22 B of shares currently outstending. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The shares outstanding for all United States stocks is significantly lower than that of the firm.
WuXi Biologics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining WuXi Biologics's current stock value. Our valuation model uses many indicators to compare WuXi Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across WuXi Biologics competition to find correlations between indicators driving WuXi Biologics's intrinsic value. More Info.WuXi Biologics is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers reporting about 0.45 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for WuXi Biologics is roughly 2.23 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the WuXi Biologics' earnings, one of the primary drivers of an investment's value.WuXi Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses WuXi Biologics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of WuXi Biologics could also be used in its relative valuation, which is a method of valuing WuXi Biologics by comparing valuation metrics of similar companies.WuXi Biologics is currently under evaluation in shares outstanding category among its peers.
WuXi Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 29.3 B | |||
| Shares Outstanding | 4.22 B | |||
| Shares Owned By Insiders | 14.17 % | |||
| Shares Owned By Institutions | 45.95 % | |||
| Price To Earning | 107.74 X | |||
| Price To Book | 5.92 X | |||
| Price To Sales | 2.11 X | |||
| Revenue | 10.29 B | |||
| Gross Profit | 4.83 B | |||
| EBITDA | 4.03 B | |||
| Net Income | 3.39 B | |||
| Cash And Equivalents | 9.86 B | |||
| Cash Per Share | 2.36 X | |||
| Total Debt | 640.51 M | |||
| Debt To Equity | 0.12 % | |||
| Current Ratio | 2.30 X | |||
| Book Value Per Share | 8.25 X | |||
| Cash Flow From Operations | 3.43 B | |||
| Earnings Per Share | 0.14 X | |||
| Price To Earnings To Growth | 0.80 X | |||
| Number Of Employees | 10.59 K | |||
| Beta | 1.09 | |||
| Market Capitalization | 34.77 B | |||
| Total Asset | 44.03 B | |||
| Z Score | 32.4 | |||
| Net Asset | 44.03 B |
About WuXi Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze WuXi Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of WuXi Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of WuXi Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.WuXi Biologics Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the Peoples Republic of China, North America, Europe, and internationally. The company was incorporated in 2014 and is headquartered in Wuxi, China. Wuxi Biologics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in WuXi Pink Sheet
WuXi Biologics financial ratios help investors to determine whether WuXi Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in WuXi with respect to the benefits of owning WuXi Biologics security.